JP7197494B2 - 抗Ｔａｕナノボディ - Google Patents

抗Ｔａｕナノボディ Download PDF

Info

Publication number
JP7197494B2
JP7197494B2 JP2019545850A JP2019545850A JP7197494B2 JP 7197494 B2 JP7197494 B2 JP 7197494B2 JP 2019545850 A JP2019545850 A JP 2019545850A JP 2019545850 A JP2019545850 A JP 2019545850A JP 7197494 B2 JP7197494 B2 JP 7197494B2
Authority
JP
Japan
Prior art keywords
tau
nanobody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505056A5 (OSRAM
JP2020505056A (ja
Inventor
ファグレト，ダニエル
ムーラン，マルセル
ゲッツィ，キャサリン
ペレ，パスカル
キエリチ，サビーネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Grenoble Alpes
Original Assignee
Universite Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Grenoble Alpes filed Critical Universite Grenoble Alpes
Publication of JP2020505056A publication Critical patent/JP2020505056A/ja
Publication of JP2020505056A5 publication Critical patent/JP2020505056A5/ja
Application granted granted Critical
Publication of JP7197494B2 publication Critical patent/JP7197494B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019545850A 2016-10-27 2017-10-27 抗Ｔａｕナノボディ Active JP7197494B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1660450 2016-10-27
FR1660450A FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau
PCT/EP2017/077691 WO2018078140A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau

Publications (3)

Publication Number Publication Date
JP2020505056A JP2020505056A (ja) 2020-02-20
JP2020505056A5 JP2020505056A5 (OSRAM) 2020-12-03
JP7197494B2 true JP7197494B2 (ja) 2022-12-27

Family

ID=58314353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019545850A Active JP7197494B2 (ja) 2016-10-27 2017-10-27 抗Ｔａｕナノボディ

Country Status (7)

Country Link
US (1) US10590191B2 (OSRAM)
EP (1) EP3532495A1 (OSRAM)
JP (1) JP7197494B2 (OSRAM)
CN (1) CN110225926B (OSRAM)
CA (1) CA3041066A1 (OSRAM)
FR (1) FR3058143B1 (OSRAM)
WO (1) WO2018078140A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CN112649615A (zh) * 2020-12-21 2021-04-13 大连理工大学 一种检测不同大小的可溶性Aβ寡聚体的方法及应用
FR3134390B1 (fr) 2022-04-11 2025-10-24 Univ Grenoble Alpes Peptide utile pour le transport de molecules au travers de barrieres cellulaires

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523742A (ja) 2011-07-14 2014-09-18 カソリック ウニヴェルシテイト ルーヴェン リン酸化タウ凝集体に対する抗体
JP2014530597A (ja) 2011-09-19 2014-11-20 アクソン ニューロサイエンス エスエー アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断
WO2015114538A1 (en) 2014-01-28 2015-08-06 F. Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
JP2015533835A (ja) 2012-10-12 2015-11-26 アリゾナ ボード オブ リージェンツ フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティ タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬
JP2016104727A (ja) 2009-08-28 2016-06-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US5882887A (en) 1994-09-12 1999-03-16 Schering Aktiengesellschaft Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP3007726B1 (en) * 2013-06-10 2020-04-08 Ipierian, Inc. Methods of treating a tauopathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104727A (ja) 2009-08-28 2016-06-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
JP2014523742A (ja) 2011-07-14 2014-09-18 カソリック ウニヴェルシテイト ルーヴェン リン酸化タウ凝集体に対する抗体
JP2014530597A (ja) 2011-09-19 2014-11-20 アクソン ニューロサイエンス エスエー アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断
JP2015533835A (ja) 2012-10-12 2015-11-26 アリゾナ ボード オブ リージェンツ フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティ タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬
WO2015114538A1 (en) 2014-01-28 2015-08-06 F. Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEBS Lett.，2004年06月18日，Vol.568, No.1-3，pp.178-182
Journal of Controlled Release，2016年10月06日，Vol.243，pp.1-10，Epub

Also Published As

Publication number Publication date
WO2018078140A1 (fr) 2018-05-03
EP3532495A1 (fr) 2019-09-04
US20190263898A1 (en) 2019-08-29
CN110225926B (zh) 2024-05-03
CN110225926A (zh) 2019-09-10
FR3058143B1 (fr) 2021-03-12
US10590191B2 (en) 2020-03-17
FR3058143A1 (fr) 2018-05-04
CA3041066A1 (fr) 2018-05-03
JP2020505056A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
JP6261621B2 (ja) アルファ−シヌクレイン抗体及びその使用
JP7357834B2 (ja) アミロイドベータに対する抗体
JP6168364B2 (ja) リン酸化タウ凝集体に対する抗体
JP6494565B2 (ja) オリゴマー特異アミロイドベータエピトープおよび抗体
JP6942358B2 (ja) Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JP6342327B2 (ja) 抗ｖｃａｍ−１ナノボディ
KR20100097651A (ko) 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도
JP2023521763A (ja) 抗ｐｈｆ－タウ抗体及びその使用
JP7197494B2 (ja) 抗Ｔａｕナノボディ
JP7254931B2 (ja) 抗アルファ－シヌクレイン抗体およびその使用
US20250289874A1 (en) Antibody against p-tau 217 and use thereof
CN118369329A (zh) 治疗神经退行性疾病的方法和物质
US20240358805A1 (en) Methods and materials to treat neurodegenerative disease
WO2016092865A1 (ja) アミロイドβの２２位及び２３位のターン構造を極めて特異的に認識する抗体
AU2016208334A1 (en) Oligomer-specific amyloid beta epitope and antibodies
HK1185350B (en) Oligomer-specific amyloid beta epitope and antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201022

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220725

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220823

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220912

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220913

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20221012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221215

R150 Certificate of patent or registration of utility model

Ref document number: 7197494

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250